EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial



Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial



Journal of Hepatology 38(1): 51-58



The efficacy and safety of rifaximin in comparison with lactitol in the treatment of acute hepatic encephalopathy was assessed in a prospective randomized, double-blind, double-dummy, controlled trial. A total of 103 patients with grade I-III acute hepatic encephalopathy were randomized to receive rifaximin (50 patients, 1200 mg/day) or lactitol (53 patients, 60 g/day) for 5-10 days. Changes in the portal-systemic encephalopathy (PSE) index on entry and at the end of the study were used to evaluate the efficacy of the two therapies. Both groups were comparable before treatment with regard to demographic data and characteristics of the hepatic encephalopathy episode. The global efficacy of both therapies was similar: 81.6% in the rifaximin group and 80.4% in the lactitol group showed improvement or total regression of the episode. A significantly better evolution of the PSE index was observed in the rifaximin group, due to a greater effect of rifaximin in two components of the index: EEG abnormalities and ammonia levels. No serious adverse events related to either treatment were found during the study. Rifaximin may be considered a useful and safe alternative therapy to lactitol in the treatment of acute hepatic encephalopathy in cirrhosis.

(PDF emailed within 1 workday: $29.90)

Accession: 045595861

Download citation: RISBibTeXText

PMID: 12480560



Related references

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology 38(1): 51-58, January, 2003

Treatment of acute hepatic encephalopathy with rifaximin in comparison with lactitol A multi-centre, double-blind, double-dummy, randomized controlled trial. Journal of Hepatology 30(SUPPL 1): 81, 1999

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Current Medical Research and Opinion 13(2): 109-118, 1993

Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 7(6): 1278-1284, 1987

Randomized controlled trial for the prevention of early post-TIPS hepatic encephalopathy Comparison between rifaximin, lactitol and no treatment. Hepatology 34(4 Pt 2): 549A, October, 2001

Lactitol in treatment of subclinical hepatic encephalopathy A double-blind placebo-controlled randomised trial. Chinese Medical Journal (English Edition) 111(2): 135, 1998

Syzygium cumini (L.) Skeels in the treatment of type 2 diabetes: results of a randomized, double-blind, double-dummy, controlled trial. Diabetes Care 27(12): 3019-3020, 2004

A multi-center, randomized, controlled, double blind and double dummy clinical trial of antofloxacin hydrochloride tablet versus levofloxacin tablet for the treatment of acute bacterial infections. Zhonghua Nei Ke Za Zhi 50(3): 225-229, 2011

Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial. Shanghai Archives of Psychiatry 27(4): 228-236, 2015

A multicenter double blind double dummy randomized controlled clinical study of prulifloxacin versus levofloxacin in the treatment of acute bacterial infections. Zhongguo Kangshengsu Zazhi 32(3): 181-186, 2007

Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterologica E Dietologica 49(1): 53-62, 2006

Comparison of a Chinese Herbal Medicine (CCH1) and Lactulose as First-Line Treatment of Constipation in Long-Term Care: A Randomized, Double-Blind, Double-Dummy, and Placebo-Controlled Trial. Evidence-Based Complementary and Alternative Medicine 2012: 923190-923190, 2012

Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial. Digestive Diseases and Sciences 32(12): 1345-1353, 1987

Comparison of the efficacy, tolerability, and smoothness indexes of two nifedipine formulations: A randomized, double-dummy, double-blind, controlled trial. Current Therapeutic Research 63(5): 305-315, 2002

Double-blind, double-dummy, randomized-controlled clinical trial on erythromycin A cyclic 11,12-carbonate versus roxithromycin. Zhongguo Kangshengsu Zazhi 28(3): 164-167, 2003